Stoffels will succeed CEO and co-founder Onno van de Stolpe, following his planned retirement.
Forty Seven's lead antibody asset has shown promising results in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Initial target is atopic dermatitis. Deal potentially worth $1.1 billion.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
| Website: | www.glpg.com |
| Email: | ir@glpg.com |
| Main Phone: | +32 15342900 |
| Address: | Generaal De Wittelaan L11 A3 |
| Address 2: | Suite 4000 |
| State: | AB |
| City / Town: | Mechelen |
| Country: | BE |
| Postal Code: | 2800 |
| Exchange: | NGS |
| CEO: | Onno van de Stolpe |
| Employees: | 1304 |
| NAICS: | Pipeline Transportation of Crude Oil(486110) |
Stoffels will succeed CEO and co-founder Onno van de Stolpe, following his planned retirement.
Forty Seven's lead antibody asset has shown promising results in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Initial target is atopic dermatitis. Deal potentially worth $1.1 billion.
Historically, Black Friday was considered as exciting for retailers as it was for the consumers snapping up deals, but the rise of online competition has changed that. Today, the increased
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
